

NT-ProBNP levels are moderately increased in acute high-altitude pulmonary edema

MINGDONG GAO^{1*}, RUIMIN WANG^{2*}, ZEPEI JIAYONG³,
YIN LIU¹ and GENYI SUN¹

¹Department of Cardiology, Tianjin Chest Hospital, Tianjin 30051; ²Department of Clinical Laboratory, Affiliated Hospital of Logistics University of Chinese People's Armed Police Forces, Tianjin 300162; ³Changdu District People's Hospital, Tibet 854000, P.R. China

Received November 4, 2012; Accepted January 16, 2013

DOI: 10.3892/etm.2013.976

Abstract. The aim of the present study was to investigate the effect of B-type natriuretic peptides (BNPs) in acute high-altitude pulmonary edema (HAPE). The study enrolled 46 subjects from lowland Han, including 33 individuals who had acutely ascended to a high altitude (21 individuals with HAPE as the case group and 12 individuals without HAPE as the high-altitude control group) and 13 healthy normal residents as the plain control group. The serum concentrations of N-terminal probrain natriuretic peptide (NT-proBNP), erythropoietin (EPO), vascular endothelial growth factor (VEGF) and nitric oxide (NO) were measured. There were significant differences in the serum concentrations of NT-ProBNP, NO, VEGF and EPO among the three groups. The serum concentrations of NT-ProBNP, EPO and VEGF were significantly higher in the HAPE patients and high-altitude control individuals than those of the plain group. No significant differences were identified between the HAPE patients and the high-altitude control group. In contrast to these three parameters, the serum concentrations of NO in the high-altitude control group were significantly higher than those of the HAPE patients and the plain group, while there were no significant differences in the serum concentrations of NO between the HAPE patients and the plain group. Furthermore, serum concentrations of NT-ProBNP and EPO were significantly reduced following treatment in the HAPE patients, however, no significant changes were identified in VEGF or NO concentrations. BNPs are increased in HAPE with severe hypoxia and right ventricular overload, but are decreased subsequent to treatment. BNPs may therefore be a potential biomarker for the diagnosis and prognosis of HAPE.

Introduction

Acute high-altitude pulmonary edema (HAPE) is a form of non-cardiogenic pulmonary edema with a normal pulmonary capillary wedge pressure. HAPE typically occurs in healthy, young individuals who ascend rapidly to altitudes >2,500 m or in residents who reascend from low altitudes to altitudes >3,000 m and/or engage in vigorous physical activities. Pulmonary edema results from the conjunction of alveolar flooding, induced by exaggerated hypoxic pulmonary hypertension, and impaired alveolar fluid clearance, which are associated with defective pulmonary transepithelial sodium transport (1). Molecular mechanisms that have been reported in HAPE cases include: i) exaggerated sympathetic activation (2), ii) defective synthesis of NO (3) or reduced bioavailability of NO mediated by free-radicals (4), iii) exaggerated endothelin-1 (ET-1) synthesis or reduced ET-1 clearance (5,6) and iv) overexpression of vascular endothelial growth factor (VEGF) (7). Natriuretic peptides have also been demonstrated to be involved in the control of hypoxic pulmonary vasoconstriction (8). However, the B-type natriuretic peptide (BNP) responses in HAPE patients remain largely unknown.

BNPs are released primarily from the ventricular myocardium in response to increased ventricular wall stress. Hypoxia is a direct, potent stimulus for BNP secretion (9). The measurement of BNP has routinely been used as a test for the diagnosis of heart failure. In particular, one study suggested the significance of BNP in pulmonary artery hypertension patients with or without right ventricular dysfunction (10). BNPs play a significant role in body fluid homeostasis and the regulation of blood pressure (11). In addition, BNPs possess antihypertrophic and antifibrotic properties, implying that they have powerful cardioprotective effects (12). In order to investigate the characteristics of BNP in HAPE, NT-proBNP, a cleavage product of the prohormone that is more stable than BNP, was measured in the serum of the HAPE patients and the controls, along with other factors associated with HAPE. The erythropoietin (EPO) level was measured as a marker for the degree of the system response to hypoxia, while NO and VEGF were measured as markers of hypoxia-induced systemic endothelial function.

Correspondence to: Professor Yin Liu, Department of Cardiology, Tianjin Chest Hospital, No. 93, Xi An Road, Tianjin 30051, P.R. China
E-mail: yinliu@126.com

*Contributed equally

Key words: BNP, high-altitude pulmonary edema, altitude sickness

Table I. Basic characteristics of the study subjects.

Characteristics	HAPE (n=21)	High-altitude controls (n=12)	Plain controls (n=12)
Age (years), mean \pm SD	31.24 \pm 11.47	36.54 \pm 10.28	35.38 \pm 10.63
Gender, male (%)	18 (85.7)	10 (83.3)	9 (75)
BMI (kg/m ²), mean \pm SD	23.85 \pm 1.21	24.33 \pm 1.29	24.07 \pm 1.19
Hypertension, n (%)	4 (19.0)	3 (25)	0 (0)

BMI, body mass index; HAPE, high-altitude pulmonary edema.

Subjects and methods

Study population. During the spring of 2010, from a total of 33 native Han individuals who had rapidly ascended from low (height <500 m) to high altitudes (height >3,000 m), 21 individuals diagnosed with HAPE and 12 individuals without HAPE were selected for the present study according to the diagnostic criteria of HAPE (13). A diagnosis of HAPE was made clinically based on the symptoms and signs gathered from an ascent to a high altitude and when no clinical evidence was identified of another cause for the hypoxemia. All chest radiographs were carefully examined to either diagnose or exclude HAPE. Chest radiographs were checked again subsequent to clinical recovery. Each diagnosis was established clinically by the same heart physician. A total of 13 age- and gender-matched normal Han individuals were randomly selected as the plain controls. Participants suffering from cardiopulmonary or altitude-related diseases were excluded.

Subsequent to being informed of the study protocol and providing written consent of their participation in the study, the subjects were interviewed and a physical examination was performed. Prior to recovery, all HAPE patients were treated in the Changdu District People's Hospital, which is located 3,200 m above sea level in the eastern part of Tibet in China.

Measurement of biochemical parameters. Venous blood was drawn from every subject for biochemical analysis. The serum was separated immediately and stored at -80°C until analysis. The blood samples obtained from the healthy lowland controls were transported to the Changdu laboratory by air to analyze them together with the other specimens. The serum concentrations of NT-proBNP, EPO, NO and VEGF were tested using commercially available kits (Biomedical Gruppe, Vienna, Austria).

Statistical analysis. The categorical variables are presented as proportions and were compared using the Chi-square tests. Continuous variables are presented as the median and the 25th and 75th percentiles and were compared using non-parametric tests. A Kruskal-Wallis H test and a Mann-Whitney U test were used for comparisons among the HAPE patients and the 2 control groups. A Wilcoxon test was used to compare the results for HAPE patients pre- and post-treatment. $P < 0.05$ was considered to indicate a statistically significant difference. All statistical procedures were performed using the SPSS 13.0 (SPSS, Inc., Chicago, IL, USA) statistical package.

Table II. Clinical characteristics of the HAPE patients (n=21).

Factors and characteristics	Ratio (%)
Symptoms and physical examination	
Moist rales in lung	21 (100)
Sinus tachycardia	14 (66.7)
Ischemic change of ST segment and/or T wave of ECG	10 (47.6)
Fever	2 (9.5)
Heart murmur	3 (14.3)
Supine position difficult	4 (19)
Bloody sputum	10 (47.6)
HACE	4 (19)
Increased WBC	8 (38.1)
Pulmonary edema on chest X ray	
Unilateral lung	2 (9.5)
Bilateral lung	15 (71.4)
Interstitial	4 (19.1)
SO ₂	
<70%	2 (9.5)
70-90%	16 (76)
>90%	3 (14.5)
Instance of illness	
First time	16 (76.2)
Second time	4 (19)
Fifth time	1 (4.8)
Possible relative etiological factor	
Catching colds	6 (28.6)
Alcoholism	1 (4.8)
Treatment	
Diuretic	8 (38.1)
Glucocorticoid	5 (23.8)
Diuretic and glucocorticoid	6 (28.6)
ACEI	4 (19.0)

Days between arrival and hospitalization: 2.9 \pm 1.87. WBC, white blood cell; HACE, high-altitude cerebral edema; ACEI, angiotensin-converting enzyme inhibitor; ECG, electrocardiogram; HAPE, high-altitude pulmonary edema; SO₂, oxygen saturation.

Results

The basic characteristics of the study subjects are shown in

Table III. Comparison among HAPE patients and two control groups.

Group	n	NT-proBNP (pg/ml) ¹	EPO (mU/ml) ²	VEGF (pg/ml) ³	NO (μmol/l) ⁴
HAPE patients ^a	21	110.33 (87.18, 147.84)	59.25 (32.25, 327.00)	108.21 (85.35, 129.68)	25.00 (20.00, 50.00)
High-altitude control ^b	12	99.80 (85.47, 109.01)	67.40 (48.25, 324.35)	100.20 (74.66, 116.70)	55.43 (46.77, 67.04)
Plain controls ^c	13	72.02 (57.83, 94.76)	25.66 (10.65, 32.86)	60.51 (46.54, 70.53)	25.00 (12.50, 50.00)
P-value		0.010	0.001	0.002	0.013

Results are medians (25th, 75th percentiles). 1: a vs. b, P=0.309; a vs. c, P=0.002; b vs. c, P=0.019. 2: a vs. b, P=0.637; a vs. c, P=0.002; b vs. c, P=0.001. 3: a vs. b, P=0.308; a vs. c, P=0.007; b vs. c, P=0.001. 4: a vs. b, P=0.005; a vs. c, P=0.559; b vs. c, P=0.030. HAPE, high-altitude pulmonary edema; EPO, erythropoietin; VEGF, vascular endothelial growth factor; NT-proBNP, N-terminal probrain natriuretic peptide.

Table IV. Comparison of HAPE patients pre- and post-treatment.

Period	n	NT-proBNP (pg/ml)	EPO (mU/ml)	VEGF (pg/ml)	NO (μmol/l)
Pre-treatment	5	110.33 (93.46, 545.37)	182.52 (71.67, 348.49)	204.52 (74.87, 222.55)	80.13 (59.36, 134.56)
Post-treatment	5	56.95 (48.86, 91.59)	43.48 (26.25, 56.68)	196.52 (94.35, 243.65)	98.16 (85.06, 108.91)
P-value		0.043	0.043	0.500	0.686

Results are medians (25th, 75th percentiles). HAPE, high-altitude pulmonary edema; EPO, erythropoietin; VEGF, vascular endothelial growth factor; NT-proBNP, N-terminal probrain natriuretic peptide.

Table I. The clinical characteristics for the HAPE patients, including symptoms, physical signs and the results of the laboratory tests, are shown in Table II.

When the 3 groups were compared there were significant differences in the serum NT-ProBNP, EPO, VEGF and NO concentrations (P=0.010, 0.001, 0.002 and 0.013, respectively). The serum concentrations of NT-ProBNP, EPO and VEGF were significantly higher in the HAPE patients and the high-altitude control individuals than those of the plain controls (P<0.05, Table III). There were no significant differences identified between the HAPE patients and high-altitude control individuals for these three parameters. By contrast, the serum concentrations of NO were significantly higher in the high-altitude control group than those of the HAPE patients and the plain group (P<0.05, Table III). There were no significant differences in the serum concentrations of NO between the HAPE patients and the plain group (Table III).

As a number of the HAPE patients left the hospital early, only 5 patients had any measurements repeated following the resolution of their symptoms. These results are shown in Table IV. Significant reductions in the NT-ProBNP and EPO levels were identified subsequent to treatment (both P=0.043), but there were no significant changes in the VEGF or NO levels (P=0.500 and 0.686, respectively).

Discussion

The results of the present study show that patients with HAPE have elevated NT-proBNP levels accompanied by higher concentrations of VEGF and EPO when compared with the plain control group, and lower NO concentrations than those of the plain or high-altitude control groups. However, the elevated NT-proBNP levels were not high enough to diagnose

heart failure. This finding is compatible with the original hypothesis of the present study and is similar to the findings of Ge *et al* (14).

A number of travellers visiting Tibet have developed HAPE, particularly those traveling by plane from the lowland region, as they have not become acclimatized to the high altitude. The causative factors identified for HAPE involve catching colds, drinking habits and excess fatigue. In the present study, subjects who were diagnosed with HAPE 5 times during 5 years may be considered as habitual HAPE sufferers. Due to delayed treatments, 4 subjects suffered acute high-altitude cerebral edema (HACE) as a complication. There were also three subjects who presented with hypertension and were consequently administered angiotensin-converting enzyme inhibitor (ACEI). Diuretics or glucocorticoids were also administered to certain patients to eliminate edema.

A previous study on ischemic coronary heart disease patients showed that the serum concentrations of BNP were always increased regardless of whether these patients had normal or impaired left ventricular ejection fractions (15). However, a second study showed that when cultured human ventricular myocytes (AC16 cells), regulated by hypoxia induced factor-1 (HIF-1), were exposed to hypoxia, BNP secretion was elevated following the augmentation of BNP gene expression, with the occurrence of activated HIF-1 identified earlier than the elevation of BNP gene expression (16). This suggests that the hypoxia-induced alterations in the BNP activity were determined at the transcriptional and translational levels (16,17). The hypoxic induction of BNP was also paralleled by the similar expression pattern and protein secretion of VEGF, another HIF-1 target factor (18). Together, these findings suggest that hypoxia directly enhances the synthesis and secretion of BNP in cardiocytes through a HIF-1α-dependent

mechanism (9,17). Identical to the findings of the present study, an increased NT-proBNP concentration was accompanied by an increased VEGF and EPO concentration. Ge *et al* (14) observed that patients with chronic mountain sickness (CMS) had higher concentrations of BNP which were proportionate to their higher pulmonary artery pressures. Furthermore, higher concentrations of BNP correlated with higher concentrations of VEGF and ET-1. However, these patients also had lower concentrations of endothelial NO synthase (eNOS).

In the present study, the NT-proBNP levels in the HAPE patients were significantly higher than those of the plain control group, although they were all lower than the diagnostic cut-off value for heart failure (19). Numerous factors are involved in HAPE, including reduced myocardial blood flow reserve (20), right ventricular overload, increased ventricular wall stress, abnormal left ventricular diastolic function (21) and changes to the transmitral inflow pattern, thus implying impaired left ventricular diastolic function (22,23). It is likely that any one of those factors is not sufficient to cause heart failure, which itself may be a triggering agent for BNP secretion in HAPE. In fact, there does not appear to be a reason that there are only differences in assay methodology present to explain the lack of increased NT-proBNP or BNP levels recorded by Toshner *et al* (24) and Feddersen *et al* (25). However, a significant rise in the levels of BNP or NT-proBNP at high-altitude have now been observed in two recent studies (26,27) and, more persuasively, none of the subjects in these studies developed HAPE or HACE.

The major physiological effects of BNP are vasodilatation, natriuresis and inhibition of the rennin-angiotensin-aldosterone and sympathetic nervous systems (28). BNP aids in avoiding the more severe hypoxic injuries in acute hypoxia and even in avoiding hypertrophy and fibrosis of cardiocytes in chronic hypoxia (12). However, the effects of diuresis and natriuresis do not correlate with BNP levels (25). It is accepted that higher levels of BNP are an indicator of an increased right ventricular load due to pulmonary artery hypertension and that the degree of elevated right heart strain may be estimated by measuring BNP or NT-proBNP concentrations (29). It may also be supposed that BNP acts as an endogenous pulmonary vasodilator, which modulates the hypoxic response (development of pulmonary artery hypertension or cardiac hypertrophy) and promotes acclimatization. However, the present study has not confirmed the role that BNP plays in the development of HAPE. The correlation of HAPE severity and BNP remains to be further investigated.

All the patients in the present study were treated in the high-altitude hospital prior to recovery, therefore there was no significant decrease in the serum levels of VEGF and no significant increase in NO subsequent to the treatment. NT-proBNP and EPO levels were significantly decreased following treatment. Together with EPO, BNP may promote resistance to hypoxia and improve accommodation through its powerful cardioprotective effects (12,30). The NO levels in the present study were not significantly increased in HAPE patients prior and subsequent to treatment, but a significant increase was observed in non-susceptible individuals. This provides important evidence that the shortage or reduced pulmonary bioavailability of NO may play a partial role in HAPE pathogeny (3,4).

The present study confirmed that NT-proBNP serum levels were significantly elevated in HAPE and that they decreased subsequent to treatment, accompanied by changes in other vasoactive substances. A decreased NT-proBNP level may be a biomarker for the recovery of HAPE subsequent to treatment. However, due to the small number of subjects in the present study, these findings require corroboration in larger groups. This is likely to lead to an improved understanding of the roles and mechanisms of BNP in HAPE.

Acknowledgements

This study was supported by the Health Bureau of Tianjin City, China and the Changdu District People's Hospital of Tibet, China. The study was approved by the ethics committee of the Tianjin Chest Hospital, China and adhered to the tenets of the Declaration of Helsinki.

References

- Scherrer U, Rexhaj E, Jayet PY, Allemann Y and Sartori C: New insights in the pathogenesis of high-altitude pulmonary edema. *Prog Cardiovasc Dis* 52: 485-492, 2010.
- Duplain H, Vollenweider L, Delabays A, Nicod P, Bärtsch P and Scherrer U: Augmented sympathetic activation during short-term hypoxia and high-altitude exposure in subjects susceptible to high-altitude pulmonary edema. *Circulation* 99: 1713-1718, 1999.
- Duplain H, Sartori C, Lepori M, *et al*: Exhaled nitric oxide in high-altitude pulmonary edema: role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. *Am J Respir Crit Care Med* 162: 221-224, 2000.
- Bailey DM, Dehnert C, Luks AM, *et al*: High-altitude pulmonary hypertension is associated with a free radical-mediated reduction in pulmonary nitric oxide bioavailability. *J Physiol* 588: 4837-4847, 2010.
- Pham I, Wuerzner G, Richalet JP, *et al*: Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans. *Eur J Clin Invest* 40: 195-202, 2010.
- Sartori C, Vollenweider L, Löffler BM, *et al*: Exaggerated endothelin release in high-altitude pulmonary edema. *Circulation* 99: 2665-2668, 1999.
- Christou H, Yoshida A, Arthur V, Morita T and Kourembanas S: Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. *Am J Respir Cell Mol Biol* 18: 768-776, 1998.
- Nakanishi K, Tajima F, Itoh H, *et al*: Changes in atrial natriuretic peptide and brain natriuretic peptide associated with hypobaric hypoxia induced pulmonary hypertension in rats. *Virchows Arch* 439: 808-817, 2001.
- Weidemann A, Klanke B, Wagner M, *et al*: Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1 α , is a direct and sufficient stimulus for brain-type natriuretic peptide induction. *Biochem J* 409: 233-242, 2008.
- Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS and Farber HW: Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. *Chest* 129: 417-425, 2006.
- McGrath MF, de Bold ML and de Bold AJ: The endocrine function of the heart. *Trends Endocrinol Metab* 16: 469-477, 2005.
- Kishimoto I, Tokudome T, Horio T, Garbers DL, Nakao K and Kangawa K: Natriuretic peptide signaling via guanylyl cyclase (GC)-A: an endogenous protective mechanism of the heart. *Curr Cardiol Rev* 5: 45-51, 2009.
- Hackett PH and Oelz O: The Lake Louise consensus on the definition and quantification of altitude illness. In: *Mountain Medicine Hypoxia*. Sutton JR, Houston CS and Coates G (eds). VT: Queen City Printers, Burlington, pp327-330, 1992.
- Ge RL, Mo VY, Januzzi JL, *et al*: B-type natriuretic peptide, vascular endothelial growth factor, endothelin-1, and nitric oxide synthase in chronic mountain sickness. *Am J Physiol Heart Circ Physiol* 300: H1427-H1433, 2011.

15. Palazzuoli A, Calabria P, Vecchiato L, *et al*: Plasma brain natriuretic peptide levels in coronary heart disease with preserved systolic function. *Clin Exp Med* 4: 44-49, 2004.
16. Casals G, Ros J, Sionis A, Davidson MM, Morales-Ruiz M and Jiménez W: Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. *Am J Physiol Heart Circ Physiol* 297: H550-H555, 2009.
17. Xia WJ, Huang YY, Chen YL, Chen SL and He JG: Acute myocardial ischemia directly modulates the expression of brain natriuretic peptide at the transcriptional and translational levels via inflammatory cytokines. *Eur J Pharmacol* 670: 7-12, 2011.
18. Lemus-Varela ML, Flores-Soto ME, Cervantes-Munguía R, *et al*: Expression of HIF-1 alpha, VEGF and EPO in peripheral blood from patients with two cardiac abnormalities associated with hypoxia. *Clin Biochem* 43: 234-239, 2010.
19. Steiner J and Guglin M: BNP or NT-proBNP? A clinician's perspective. *Int J Cardiol* 129: 5-14, 2008.
20. Kaufmann BA, Bernheim AM, Kiencke S, *et al*: Evidence supportive of impaired myocardial blood flow reserve at high-altitude in subjects developing high-altitude pulmonary edema. *Am J Physiol Heart Circ Physiol* 294: H1651-H1657, 2008.
21. Mahmud E, Raisinghani A, Hassankhani A, *et al*: Correlation of left ventricular diastolic filling characteristics with right ventricular overload and pulmonary artery pressure in chronic thromboembolic pulmonary hypertension. *J Am Coll Cardiol* 40: 318-324, 2002.
22. Allemann Y, Rotter M, Hutter D, *et al*: Impact of acute hypoxic pulmonary hypertension on LV diastolic function in healthy mountaineers at high altitude. *Am J Physiol Heart Circ Physiol* 286: H856-H862, 2004.
23. Mason NP, Petersen M, Melot C, *et al*: Serial changes in nasal potential difference and lung electrical impedance tomography at high-altitude. *J Appl Physiol* 94: 2043-2050, 2003.
24. Toshner MR, Thompson AA, Irving JB, *et al*: NT-proBNP does not rise on acute ascent to high-altitude. *High Alt Med Biol* 9: 307-310, 2008.
25. Feddersen B, Ausserer H, Haditsch B, Frisch H, Noachtar S and Straube A: Brain natriuretic peptide at altitude: relationship to diuresis, natriuresis, and mountain sickness. *Aviat Space Environ Med* 80: 108-111, 2009.
26. Woods D, Hooper T, Hodkinson P, *et al*: Effects of altitude exposure on brain natriuretic peptide in humans. *Eur J Appl Physiol* 111: 2687-2693, 2011.
27. Woods DR, Begley J, Stacey M, Smith C, Boos CJ, Hooper T, Hawkins A, Hodkinson P, Green N and Mellor A: Severe acute mountain sickness, brain natriuretic peptide and NT-proBNP in humans. *Acta Physiol (Oxf)* 205: 349-355, 2012.
28. Yoshimura M, Yasue H and Ogawa H: Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. *Can J Physiol Pharmacol* 79: 730-735, 2001.
29. Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr C, Vogeser M and Behr J: Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. *Chest* 128: 2368-2374, 2005.
30. McGrath MF, de Bold ML and de Bold AJ: The endocrine function of the heart. *Trends Endocrinol Metab* 16: 469-477, 2005.